🔴 Pyxis Oncology is trading 11% down today after confirmed response rate fell to 36%

Pyxis Oncology is trading 11.05% down now at $3.46 after updated Phase 1 MICVO data showed a 36% confirmed response rate in 33 evaluable patients.

• The company reported a 94% disease-control rate.
• The response rate declined from the previously reported 46%, prompting concerns about efficacy durability and valuation uncertainty.
• Broader risk-off sentiment pressured biotechnology shares as major U.S. indices fell.